A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine

Medical Devices: Evidence and Research

Volumn 4, Issue 1, 2011, Pages 83-89

  Ikushima, Ichiro ^a   Yonenaga, Kazuchika ^a   Iwakiri, Hironao ^a   Nagoshi, Hideki ^a   Kumagai, Haruhito ^a   Yamashita, Yasuyuki ^b  

^a Miyakonojo Medical Association Hospital   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cilostazol; Peripheral arterial disease; Primary patency rate; Stent; Superficial femoral artery; Ticlopidine

Indexed keywords

CILOSTAZOL; PATENCY RATES; PERIPHERAL ARTERIAL DISEASE; STENT; SUPERFICIAL FEMORAL ARTERIES; TICLOPIDINE;

PYRIDINE;

ACETYLSALICYLIC ACID; CILOSTAZOL; TICLOPIDINE;

ADULT; AGED; ANGIOPLASTY; ARTICLE; BYPASS SURGERY; CLINICAL ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IN-STENT RESTENOSIS; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODEL; RECANALIZATION; RESTENOSIS; RETROSPECTIVE STUDY; RISK REDUCTION; STENT; SUPERFICIAL FEMORAL ARTERY; TREATMENT INDICATION;

EID: 80051712051     PISSN: None     EISSN: 11791470     Source Type: Journal    
DOI: 10.2147/MDER.S21629     Document Type: Article

References (35)

1. Cheng SW, Ting AC, Ho P. Angioplasty and primary stenting of highgrade, long-segment superficial femoral artery disease: is it worthwhile? Ann Vasc Surg. 2003;17:430-437.
2. Conroy RM, Gordon IL, Tobis JM, et al. Angioplasty and stent placement in chronic occlusion of the superficial femoral artery: technique and results. J Vasc Interv Radiol. 2000;11:1009-1020.
3. Gray BH, Olin JW. Limitations of percutaneous transluminal angioplasty with stenting for femoropopliteal arterial occlusive disease. Semin Vasc Surg. 1997;10:8-16.
4. Lugmayr HF, Holzer H, Kastner M, Riedelsberger H, Auterith A. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm follow-up. Radiology. 2002;222:37-43.
5. Martin EC, Katzen BT, Benenati JF, et al. Multicenter trial of the wallstent in the iliac and femoral arteries. J Vasc Interv Radiol. 1995;6:843-849.
6. Sabeti S, Schillinger M, Amighi J, et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel selfexpanding stents: propensity score-adjusted analysis. Radiology. 2004;232:516-521.
7. Sapoval MR, Long AL, Raynaud AC, et al. Femoropopliteal stent placement: long-term results. Radiology. 1992;184:833-839.
8. Schlager O, Dick P, Sabeti S, et al. Long-segment SFA stenting-the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther. 2005;2:676-684.
9. Vogel TR, Shindelman LE, Nackman GB, Graham AM. Efficacious use of nitinol stents in the femoral and popliteal arteries. J Vasc Surg. 2003;38:1178-1184.
10. Ge J, Han Y, Jiang H, Sun B, Chen J, Zhang S, Du Z; On behalf of the RACTS (A Randomized Prospective Antiplatelet Trial of Cilostazol Versus Ticlopidine in Patients Undergoing Coronary Stenting) Trial Investigators. RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. J Cardiovasc Pharmacol. 2005;46:162-166.
11. Kozuma K, Hara K, Yamasaki M, et al. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J. 2001;141:124-130.
12. Park SW, Lee CW, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 2000;86:499-503.
13. Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol. 1998;82:144-147.
14. Take S, Matsutani M, Ueda H, et al. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1997;79:1097-1099.
15. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100:21-26.
16. Zhang Z, Foster JK, Kolm P, et al. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. Am Heart J. 2006;152:770-776.
17. Suzuki K, Iida O, Soga Y, et al. Long-term results of the S.M.A.R.T. Control (TM) stent for superficial femoral artery lesions, J-SMART registry. Circ J. 2011;75:939-944.
18. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg. 2008;48:144-149.
19. Soga Y, Iida O, Hirano K, Yokoi H, Nanto S, Nobuyoshi M. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010;52:608-615.
20. Soga Y, Yokoi H, Kawasaki T, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol. 2009;53:48-53.
21. Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007;3:229-234.
22. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischemia of the leg (BASIL): multicentre, randomized controlled trial. Lancet. 2005;366:1925-1934.
23. Becquemin JP, Favre JP, Marzelle J, Nemoz C, Corsin C, Leizorovicz A. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg. 2003;37:487-494.
24. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12:23-31.
25. Grimm J, Muller-Hulsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001;12:935-942.
26. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: a comparative randomized study. Cardiovasc Intervent Radiol. 1997;20:420-425.
27. Zdanowski Z, Albrechtsson U, Lundin A, et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? a randomized controlled study. Int Angiol. 1999;18:251-255.
28. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888.
29. Strecker EP, Boos IB, Gottmann D. Femoropopliteal artery stent placement: evaluation of long-term success. Radiology. 1997;205:375-383.
30. Strecker EP, Boos IB, Gottmann D, Vetter S. Clopidogrel plus longterm aspirin after femoro-popliteal stenting. The CLAFS project: 1-and 2-year results. Eur Radiol. 2004;14:302-308.
31. Strecker EP, Gottmann D, Boos IB, Vetter S. Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent stenosis: preliminary results of an ongoing study. Cardiovasc Intervent Radiol. 1998;21:375-379.
32. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041-2050.
33. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523-530.
34. Dawson DL, DeMaioribus CA, Hagino RT, et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg. 1999;178:141-146.
35. Mohler ER 3rd, Beebe HG, Salles-Cuhna S, et al. Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. Vasc Med. 2001;6:151-156.